A joint venture of the University Hospitals Cologne and Bonn and the Faculties of Mathematics and Natural Sciences of the Universities of Cologne and Bonn, the Mildred Scheel School of Oncology Cologne-Bonn (MSSO Cologne-Bonn) will further the careers of the brightest minds in translational cancer research and trains a new generation of physician and medical scientists to accelerate the development of novel cancer therapies.
A more than necessary step since modern-day cancer therapy is witnessing a paradigm shift, away from globally toxic chemo- and radiotherapy, towards the use of non-genotoxic targeted small molecules and antibodies. The advent of modern technologies, particularly genome sequencing and high-performance computational biology, has revolutionized cancer research. These knowledge gains led to the development and clinical implementation of numerous novel drugs.
MD Research Stipends
Theundergraduate program prepares highly qualified and outstanding MD students during a 12 months study leave for a scientific career in the field of translational cancer research by integrating them into ongoing research projects.
Ourpostgraduate program involves an extended period of intensive research and scientific training. This program takes advantage of the wide range of oncological expertise, with the opportunity to gain the degree of Dr. nat. med..
Junior Research Groups
Another majorgoal is to support junior research group leaders. An excellent opportunity for a new generation of translational cancer researchers to further their academic career for the rapid setting-up of an autonomous research team.
Hier gelangen Sie direkt weiter zur Homepage der › Mildred Scheel School of Oncology.
Leitung Projektmanagement und Innovationsmanagement
Michael Neumann, Dipl. Ges.-Ök.
Abteilung für Integrierte Onkologie
Tel.: +49 (0) 228 287 13611